focus -WSS

focus

author：fashion 2025-10-02 17:22:57 - browse：793

Pascal Soriot - Senate Finance Committee — AstraZeneca CEO Pascal Soriot Jacquelyn Martin/AP

LONDON — Medicare’s first-ever drug pricing negotiations are officially underway. But neither government officials nor drugmakers are wanting to show their cards, at least publicly.

Last week, Medicare made its first offers to the makers of the 10 products subject to negotiation, though it said it would be up to the companies to discuss the proposals. On Thursday, at a press briefing at which they presented their 2023 earnings, AstraZeneca executives also played coy about the bargaining over the price of the company’s diabetes drug Farxiga.

“We have received the first offer, but as you can imagine, we will not disclose what the offer is,” Ruud Dobber, the company’s executive vice president of biopharmaceuticals business, said at the event, held at the London Stock Exchange. “We are in active negotiation, and it will be a few rounds of discussions” with Medicare.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Kellogg’s is going to war over Mexico’s nutrition label rules

knowledge

entertainment

WSS

Chemotherapy before breast cancer surgery might fuel metastasis

HHS's proposed rule does nothing to address the climate crisis

How a small hospital in rural Puerto Rico survived Hurricane Maria

FDA advisory panel to debate high blood pressure devices

How the first Native Hawaiian psychiatrist helped diversify medicine

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

hotspot

focus

knowledge

Medical leaders decry Supreme Court decision on affirmative action

Class action alleges UnitedHealth concealed DOJ probe

23andMe had bad news about my health. I wish a person had delivered it

How the drug

What does generative AI mean for health care? We asked experts

Health officials lay out plans to cope with respiratory virus season

Hepatitis C has a cure — but many Americans still lack access to it

Kellogg’s is going to war over Mexico’s nutrition label rules

The high cost of giving birth even with insurance

The creative science of coining drug names

leisure time

Empower primary care with adequate payments and technology

Intellia plays down concerns on accidental germline transmission

Has Bernie Sanders reached the limit of his pharma bullying effort?

Welsh Carson private equity firm escapes from FTC antitrust case

As health system earnings go up, health insurance stocks go down

Intellia plays down concerns on accidental germline transmission

knowledge

focus

entertainment

focus